Oragenics Inc. is a biotechnology company that focuses on the development and commercialization of pharmaceutical products for oral health and infectious diseases. The company is engaged in the creation of novel therapies utilizing its proprietary biological platform technologies. A key area of its research is aimed at the development of antibiotics to combat resistant strains of bacteria, often addressing public health challenges that require innovative solutions. Oragenics primarily targets sectors that include pharmaceuticals, healthcare, and biotherapeutics, impacting both consumer and clinical markets. The company is headquartered in Tampa, Florida, and continues to play a significant role in pioneering research within its niche, contributing to advancements in medical science and therapeutic options. By leveraging cutting-edge research in microbiomics, Oragenics is not only integral to addressing significant health concerns but also a notable contributor to the broader biotechnology and pharmaceutical industries.